LONDON, ONTARIO--(Marketwire - December 23, 2010) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced today that it has filed an Amended Statement of Executive Compensation (Statement) Form 51-102F6 (Form) following a review by the Ontario Securities Commission. The amended Statement provides enhanced disclosure around the Company's stock option awards and those disclosures required in tabular format have been revised identically to the guidance provided in the Form.
About Critical Outcome Technologies Inc. (COTI)
COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for accelerated identification and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI is focused on preparing its lead anti-cancer compound, COTI-2, for an Investigational New Drug filing in the USA in 2011. In addition to COTI-2, the company has a significant preclinical pipeline targeting market opportunities such as: acute myelogenous leukemia and other cancers, multiple sclerosis, HIV integrase, and Alzheimer's disease.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.